# EDGAR Filing Document

**Accession Number:** 0001607962
**File Stem:** 0001213900-26-056839
**Filing Date:** 2026-5
**Character Count:** 7297
**Document Hash:** 6d822cb078599a2b3489d598f34d7855
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-056839.hdr.sgml**: 20260514

**ACCESSION NUMBER**: 0001213900-26-056839

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260325

**FILED AS OF DATE**: 20260514

**DATE AS OF CHANGE**: 20260514

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** ORAMED PHARMACEUTICALS INC.
- **CENTRAL INDEX KEY:** 0001176309
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36612
- **FILM NUMBER:** 26980499

**BUSINESS ADDRESS:**
- **STREET 1:** 1185 AVENUE OF THE AMERICAS, 3RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 646-844-1164

**MAIL ADDRESS:**
- **STREET 1:** 1185 AVENUE OF THE AMERICAS, 3RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036

**FORMER NAME:**
- **FORMER CONFORMED NAME:** Integrated Security Technologies, Inc.
- **DATE OF NAME CHANGE:** 20040614

**FORMER NAME:**
- **FORMER CONFORMED NAME:** IGUANA VENTURES LTD
- **DATE OF NAME CHANGE:** 20020625
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lifeward Ltd.
- **CENTRAL INDEX KEY:** 0001607962
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 2 CABOT ROAD
- **CITY:** HUDSON
- **STATE:** MA
- **ZIP:** 01749
- **BUSINESS PHONE:** 15082511154

**MAIL ADDRESS:**
- **STREET 1:** 2 CABOT ROAD
- **CITY:** HUDSON
- **STATE:** MA
- **ZIP:** 01749

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ReWalk Robotics Ltd.
- **DATE OF NAME CHANGE:** 20140620

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Argo Medical Technologies Ltd.
- **DATE OF NAME CHANGE:** 20140513

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>ORAMED PHARMACEUTICALS INC.<br><sub>(Last) (First) (Middle)</sub><br>1185 AVENUE OF THE AMERICAS, THIRD FLOOR<br><sub>(Street)</sub><br>NEW YORK, NY 10036<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Lifeward Ltd. [ LFWD ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-25 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 1250363 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Warrants (right to buy) | <sup>(1)</sup> | <sup>(2)</sup> | Ordinary Shares | 1006113 | $0 | D |  |
| Warrants (right to buy) | <sup>(3)</sup> | 2031-03-25 | Ordinary Shares | 1296296 | $5.40 | D |  |
| Warrants (right to buy) | <sup>(4)</sup> | 2031-03-25 | Ordinary Shares | 1666666 | $5.40 | D |  |
| Senior Secured Convertible Notes | <sup>(5)</sup> | <sup>(6)</sup> | Ordinary Shares | 1666666 | $5.40 | D |  |

---

### Footnotes:

(1) Pursuant to the terms of the pre-funded warrants (the "Pre-Funded Warrants"), Lifeward Inc. (the "Issuer") may not effect any exercise of the Pre-Funded Warrants, and Oramed Pharmaceuticals Inc. (the "Reporting Person") may not exercise the Pre-Funded Warrants, to the extent that after giving effect to such issuance after exercise, the Reporting Person would beneficially own more than 49.99% of the outstanding ordinary shares, no par value ("Ordinary Shares") of the Issuer (the "49.99% Beneficial Ownership Limitation").

(2) Subject to the 49.99% Beneficial Ownership Limitation, the Pre-Funded Warrants are freely exercisable.

(3) Pursuant to the terms of the share purchase warrants (the "Share Purchase Warrants"), the Issuer may not effect any exercise of the Share Purchase Warrants, and the Reporting Person may not exercise the Share Purchase Warrants, to the extent that after giving effect to such issuance after exercise, the Reporting Person would beneficially own more than 49.99% of the Ordinary Shares.

(4) Pursuant to the terms of the purchase agreement warrants (the "Purchase Agreement Warrants"), the Issuer may not effect any exercise of the Purchase Agreement Warrants, and the Reporting Person may not exercise the Purchase Agreement Warrants, to the extent that after giving effect to such issuance after exercise, the Reporting Person would beneficially own more than 45.0% of the Ordinary Shares.

(5) Pursuant to the terms of the senior secured convertible notes (the "Notes"), the Issuer may not effect any conversion of the Notes, and the Reporting Person may not convert the Notes, to the extent that after giving effect to such issuance after conversion, the Reporting Person would beneficially own more than 45.0% of the Ordinary Shares (the "45% Beneficial Ownership Limitation").

(6) Subject to the 45% Beneficial Ownership Limitation, the Notes are freely convertible.

**Signature:** By: /s/ Avraham Gabay Name: Avraham Gabay Title: Chief Financial Officer  
**Date:** 2026-05-14

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**